MIV Therapeutics Coverage Initiated by Investrend Affiliate SISM Research Analyst Ernest C. Schlotter


NEW YORK, Sept. 16, 2003 (PRIMEZONE) -- Coverage of MIV Therapeutics Inc. (OTCBB:MIVT) (Berlin:MIV) has been initiated by Ernest C. Schlotter, a research analyst with SISM Research & Investment Services, an Investrend Research affiliate.

MIV Therapeutics Inc.'s corporate mission is to become a world leader in the development of coatings for stents and other medical devices as well as drug delivery systems for the treatment of cardiovascular disease (with an emphasis on reducing restenosis) and for localized drug delivery in other diseased organs of the body.

MIVT is in late stage development of a unique proprietary hydroxyapatite (HAp) biocompatible stent coating technology. This HAp coating technology could potentially revolutionize the current $2.6 billion coronary stent market. The stent market is expected to grow to $6 billion by 2006 as a direct result of coatings and therapeutics.

MIVT has focused the development of its hydroxyapatite technology on two applications: as a fully biocompatible coating for stents and as a stent drug delivery system. Hydroxyapatite is found in the body's hard tissue, e.g., bones and teeth, and the natural properties of the coating will most surely be an attractive alternative to the polymer coatings currently being developed by the industry. HAp has the potential to become the "coating of choice" for all stent delivery systems.

SISM Research & Investment Services, based in Zurich, Switzerland, is a private firm offering a variety of investment and financial services since 1995. SISM Research writes, publishes and distributes investment research coverage, in both English and German, on public companies trading on the OTC Bulletin Board, NASDAQ and AMEX, with coverage geared toward institutional and individual investors in both North America and Europe.

SISM Research is a member of the FIRST Research Consortium, a collaborative of the world's leading independent fee-based equity research firms. SISM Research is distributed to the world's leading financial databases and electronic trader stations via Investrend Research Syndicate. The fee for this coverage of $16,500 is being paid by MIV Therapeutics Inc. solely to insure independence and no one associated with SISM Research may own or trade the equities of companies under coverage.

Anyone interested in receiving alerts regarding MIV research or webcasts should e-mail info@investrend.com with "MIVT" in the subject line, or click on http://www.investrend.com/contact.asp.



            

Contact Data